Endocrine effects of adjuvant letrozole + triptorelin compared with tamoxifen + triptorelin in premenopausal patients with early breast cancer

What Was Tested

The paper reports a study of Triptorelin, published as a randomized controlled trial.

To compare the endocrine effects of 6 months of adjuvant treatment with letrozole + triptorelin or tamoxifen + triptorelin in premenopausal patients with early breast cancer within an ongoing phase 3 trial (Hormonal Adjuvant Treatment Bone Effects study).

Who Took Part

The study group was 81 women.

PubMed indexes the participants as adults and middle-aged adults, women only.

Prospectively collected hormonal data were available for 81 premenopausal women, of whom 30 were assigned to receive tamoxifen + triptorelin and 51 were assigned letrozole + triptorelin +/- zoledronate.

Serum 17-beta-estradiol (E2), follicle-stimulating hormone (FSH), luteinizing hormone (LH), Delta4-androstenedione, testosterone, dehydroepiandrosterone-sulfate, progesterone, adrenocorticotropic hormone (ACTH), and cortisol were measured at baseline and after 6 months of treatment.

How the Study Was Run

The researchers set it up as a randomized study.

Because people in this Triptorelin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

A time span of 6 months appears in the methods.

For each hormone, 6-month values were compared between treatment groups by the Wilcoxon-Mann-Whitney exact test.

What Was Measured

PubMed files the paper under topics including Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Chemotherapy, Adjuvant, Gonadal Hormones, Letrozole, Nitriles and Premenopause.

What This Means in Plain Language

The paper is a randomized study of Triptorelin in 81 women over 6 months.

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2008 (Journal of clinical oncology : official journal of the American Society of Clinical Oncology), a journal based in United States.

More context: the Triptorelin compound page.